In most of the world, the oldest old are the fastest growing segment of the population and the individuals most affected by cognitive decline and dementia. The 90+ Study, a population-based sample of more than 1600 people aged 90 years and older (Laguna Woods, California), comprises one of the largest longitudinal studies of oldest old in the world. Participants (76% women; mean age 97 years) are followed every 6 months with neuropsychological and neurological examinations, medical record review, informant questionnaires and interviews. DNA and brain donation are also requested. Our study, similar to other investigations, shows high prevalence and incidence rates of dementia that continue to increase with age in oldest old individuals. However, most individuals without dementia also show significant age-associated declines in cognitive performance. The underlying biological mechanisms of these declines in the oldest old are poorly understood. Amyloid and other pathologies are frequently present in both demented and non-demented 90+ year olds, and distinguish poorly between the groups. Moreover, rates of cognitive decline do not appear to differ in non-demented oldest old with and those without significant amyloid and AD pathology. These results have called into question the relevance of amyloid in the expression of cognitive loss and dementia in oldest old. More recent results however from the 90+ Study suggest that the relationship between pathology and cognition may be more complex, and that the number as well as the types of pathologies may indeed be relevant for cognitive performance in aging. The relationship of cognitive declines in 90+ individuals to cerebral amyloid and other pathologies (identified by imaging and by autopsy) will be presented. Implications for the understanding of dementia and cognition at all ages will be considered. 
In most of the world, the oldest old are the fastest growing segment of the population and the individuals most affected by cognitive decline and dementia. The 90+ Study, a population-based sample of more than 1600 people aged 90 years and older (Laguna Woods, California), comprises one of the largest longitudinal studies of oldest old in the world. Participants (76% women; mean age 97 years) are followed every 6 months with neuropsychological and neurological examinations, medical record review, informant questionnaires and interviews. DNA and brain donation are also requested. Our study, similar to other investigations, shows high prevalence and incidence rates of dementia that continue to increase with age in oldest old individuals. However, most individuals without dementia also show significant age-associated declines in cognitive performance. The underlying biological mechanisms of these declines in the oldest old are poorly understood. Amyloid and other pathologies are frequently present in both demented and non-demented 90+ year olds, and distinguish poorly between the groups. Moreover, rates of cognitive decline do not appear to differ in non-demented oldest old with and those without significant amyloid and AD pathology. These results have called into question the relevance of amyloid in the expression of cognitive loss and dementia in oldest old. More recent results however from the 90+ Study suggest that the relationship between pathology and cognition may be more complex, and that the number as well as the types of pathologies may indeed be relevant for cognitive performance in aging. The relationship of cognitive declines in 90+ individuals to cerebral amyloid and other pathologies (identified by imaging and by autopsy) will be presented. Implications for the understanding of dementia and cognition at all ages will be considered. Results. DR's EXTRA study is a four-year RCT studying the effects of regular exercise and healthy diet. The preliminary results indicate significant benefit of the intervention on cognition among persons 65 years. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) is ongoing multi-domain intervention designed to delay cognitive impairment among risk individuals. The 2-year intervention has four main components: nutritional guidance; exercise; cognitive training and social activity; monitoring/management of vascular risk factors. Preliminary results indicate several positive lifestyle changes and low drop-out rate (11 % after 2 years). Two-years intervention will be finished in the beginning of 2014. EDPI is a recently established network between ongoing multi-domain RCTs in Europe (FINGER, MAPT, preDIVA) and pooled data will provide valuable information for future multi-national RCTs. EDPI has recently started the Healthy Aging Through Internet Counseling in the Elderly (HATICE) project to clarify the efficacy of a multi-domain intervention based on internet-based platform. Conclusions. Multifactorial etiology of AD points the importance of multidomain interventions (pharmacological and non-pharmacological) to effectively delay dementia onset. Experiences from the recent multi-domain intervention studies are positive and indicate that it is possible to change lifestyle and prevent or delay cognitive impairment even among elderly persons. International collaboration is necessary to initiate future large-scale dementia prevention studies.
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The AbO hypothesis for AD was introduced in 1998. It proposed that neuron damage leading to dementia was instigated by diffusible oligomeric Ab toxins. The proposed mechanism was disruption of neuronal signal transduction triggered by ligand-like binding of AbOs to unknown toxin receptors. The hypothesis is supported by experimental findings that AbOs can target specific synapses, disrupt plasticity and memory mechanisms, and induce AD-type pathology; it is strengthened, moreover, by data showing AD-dependent accumulation of toxic AbOs in humans and animal models. Surprisingly, molecular interactions between AbOs and neuron surfaces are still a conundrum, although key pieces of the puzzle have been found. The extracellular presence of AbOs is indicated by detection of AbOs in AD CSF, albeit at low levels. The involvement of surface-bound AbOs is indicated by the ability of AbO antibodies delivered intra-nasally to target the hippocampal neuropil of AD Tg mice (suggesting intranasal antibody delivery could be of value for therapeutics and for early diagnostic PET imaging). Interactions between extracellular AbOs and brain cell surfaces appear to depend on multiple cell surface proteins. Although these proteins often are proposed as AbO receptors, the important interactions may be less direct. Emblematic of this complexity is the PrP protein, whose involvement in AbO toxicity is extensively documented. Nonetheless, we find that when PrP is virtually eliminated from differentiated hippocampal neurons by siRNA (delivered with high efficiency by nanoparticles) or by enzymatic surface removal of PrP (using PIPLC), there is no loss of synaptic AbO accumulation. Analogously, nano-scale artificial membranes (Nanodiscs) containing solubilized synaptic membrane proteins show no loss of AbO specific binding after PrP removal. At present, a full understanding of AbO binding sites and transduction mechanisms is still not available. Synaptic Nanodiscs, however, with a full complement of membrane proteins including unidentified AbO binding sites, provide an unbiased platform to screen small molecule libraries for antagonist useful as therapeutic lead compounds.
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